Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. That said, here are three profitable companies to steer clear of and a few better alternatives.
DigitalOcean (DOCN)
Trailing 12-Month GAAP Operating Margin: 17.4%
Built for simplicity in a world of complex cloud solutions, DigitalOcean (NYSE: DOCN) provides a simplified cloud computing platform that enables developers and small businesses to quickly deploy and scale applications.
Why Does DOCN Give Us Pause?
- Customers have churned over the last year due to the commoditized nature of its software, as reflected in its 99.8% net revenue retention rate
- Sky-high servicing costs result in an inferior gross margin of 59.9% that must be offset through increased usage
- Operating profits increased over the last year as the company gained some leverage on its fixed costs and became more efficient
At $67.00 per share, DigitalOcean trades at 7x forward price-to-sales. Check out our free in-depth research report to learn more about why DOCN doesn’t pass our bar.
Toll Brothers (TOL)
Trailing 12-Month GAAP Operating Margin: 16.1%
Started by two brothers who started by building and selling just one home in Pennsylvania, today Toll Brothers (NYSE: TOL) is a luxury homebuilder across the United States.
Why Do We Think Twice About TOL?
- Backlog has dropped by 9.4% on average over the past two years, suggesting it’s losing orders as competition picks up
- Sales are projected to tank by 6.5% over the next 12 months as demand evaporates
- Earnings growth underperformed the sector average over the last two years as its EPS grew by just 3.6% annually
Toll Brothers’s stock price of $137.28 implies a valuation ratio of 11.3x forward P/E. Read our free research report to see why you should think twice about including TOL in your portfolio.
Regeneron (REGN)
Trailing 12-Month GAAP Operating Margin: 24.9%
Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ: REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders.
Why Are We Wary of REGN?
- Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 4.6% over the last two years was below our standards for the healthcare sector
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 26.8 percentage points
- Eroding returns on capital suggest its historical profit centers are aging
Regeneron is trading at $744.84 per share, or 17.2x forward P/E. To fully understand why you should be careful with REGN, check out our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
